Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
Status:
Completed
Trial end date:
2019-01-02
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn more about the safety of giving
sunitinib to patients with metastatic kidney cancer for 2 weeks followed by 1 week in which
they receive no drug. Researchers want to learn more about the side effects of the drug and
the effects of a different dosing schedule.